Rheumatic immune-related adverse events with immune checkpoint inhibitors more severe than previously reported

For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually mean oregon severe, with much than one-third starring to imperishable ICI discontinuation, according to a survey published online Sept. 8 successful ACR Open Rheumatology.